1. P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY "RETE EMATOLOGICA PUGLIESE". (5th April 2022) Authors: Mele, G; Cascavilla, N; Di Renzo, N; Guarini, A; Mazza, P; Melillo, L; Pavone, V; Tarantini, G; Curci, P; Falcone, AP; Germano, C; Mele, A; Palazzo, G; Palumbo, G; Reddiconto, G; Rossini, B; Specchia, G; Musto, P; Pastore, D Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY "RETE EMATOLOGICA PUGLIESE". (5th April 2022) Authors: Mele, G; Cascavilla, N; Di Renzo, N; Guarini, A; Mazza, P; Melillo, L; Pavone, V; Tarantini, G; Curci, P; Falcone, AP; Germano, C; Mele, A; Palazzo, G; Palumbo, G; Reddiconto, G; Rossini, B; Specchia, G; Musto, P; Pastore, D Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗